Segment and Related Information (Tables)

12 Months Ended

Jun. 30, 2014

Schedule of Segment Performance Based on Income (Loss) from Continuing Operations before Interest Income and Other Income and Expense

The accounting policies of the segments are the same as those described in the summary of significant accounting policies (Note 1). The Company evaluates segment performance based on income (loss) before interest income and other income and expense.

(In thousands)	Research			Molecular diagnostics		Pharmaceutical & clinical services			Total
Year ended June 30, 2014:
Revenues	$	—		$	748,198	$	30,018		$	778,216
Depreciation and amortization		2,001			9,887		1,931			13,819
Segment operating income (loss)		(64,981	)		338,020		1,403			274,442
Year ended June 30, 2013:
Revenues	$	—		$	582,392	$	30,773		$	613,165
Depreciation and amortization		2,182			4,974		1,733			8,889
Segment operating income (loss)		(56,428	)		291,509		(7,079	)		228,002
Year ended June 30, 2012:
Revenues	$	—		$	472,390	$	23,615		$	496,005
Depreciation and amortization		2,021			5,395		1,653			9,069
Segment operating income (loss)		(49,231	)		237,737		(8,188	)		180,318

	Years Ended June 30,
(In thousands)	2014			2013			2012
Total operating income for reportable segments	$	274,442		$	228,002		$	180,318
Unallocated amounts:
Interest income		5,397			5,497			4,629
Other		(1,974	)		(223	)		(407	)
Income from operations before income taxes		277,865			233,276			184,540
Income tax provision		101,640			86,137			72,389
Net income	$	176,225		$	147,139		$	112,151

Schedule Of Comparison of Balance Sheet Assets by Operating Segment

The following table sets forth a comparison of balance sheet assets by operating segment:

(In thousands)	June 30,
	2014		2013
Net equipment and leasehold improvements:
Research	$	8,199	$	8,590
Molecular diagnostics		24,316		15,769
Pharmaceutical and clinical services		2,079		3,243
Total	$	34,594	$	27,602
Total Assets:
Research	$	67,999	$	82,517
Molecular diagnostics		409,795		110,329
Pharmaceutical and clinical services		75,434		79,911
Total	$	553,228	$	272,757

Reconciliation of Assets by Operating Segment to Total Assets

The following table reconciles assets by operating segment to total assets:

	June 30,
(In thousands)	2014		2013
Total assets by segment	$	553,228	$	272,757
Cash, cash equivalents, and marketable investment securities (1)		270,586		531,064
Total	$	823,814	$	803,821

(1) The Company manages cash, cash equivalents, and marketable investment securities at the consolidated level for all segments